title: Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx.
abstract: Cetuximab (CTX) is used for the concurrent treatment with radiotherapy (RT) in squamous cell carcinoma of head and neck (HNSCC). There are no reliable clinical predictive markers of effectiveness of CTX at yet. We describe the clinical case of patient who received a CTX/RT to cure locoregionally advanced hypopharyngeal SCC. 2-Deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography and computed tomography ((18)FDG-PET/CT) was performed before the treatment and repeated 10 days after CTX induction dose. A repeated (18)FDG-PET/CT scan showed dramatic decrease of metabolic parameters. Patient had a complete response after treatment and is still alive and cured after 5 years.
authors.affiliation: Department of Radiation Oncology, National Cancer Institute, Vilnius, Lithuania. Electronic address: mindaugas7415@gmail.com.
authors.forename: Mindaugas
authors.initials: M
authors.lastname: Grybauskas
authors.affiliation: Department of Radiation Oncology, Clinique et Maternité Sainte-Elisabeth, Namur, Belgium.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Daisne
authors.affiliation: Radiotherapy and Drug Therapy Centre, National Cancer Institute, Vilnius, Lithuania; Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
authors.forename: Eduardas
authors.initials: E
authors.lastname: Aleknavičius
authors.affiliation: Department of Radiation Oncology, National Cancer Institute, Vilnius, Lithuania.
authors.forename: Arvydas
authors.initials: A
authors.lastname: Burneckis
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D000068818:Cetuximab / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000379:methods*; D019788:Fluorodeoxyglucose F18 / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000628:therapy*; D008297:Male; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D000077195:Squamous Cell Carcinoma of Head and Neck; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000068818:Cetuximab
keywords: Cetuximab; FDG-PET/CT; Head and neck cancer; Predictive marker; Radiotherapy